{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["31(9)"],"submitter":["Fasching PA"],"funding":["Novartis Pharmaceuticals Corporation (NPC)","Novartis Pharmaceuticals Corporation"],"pubmed_abstract":["<h4>Purpose</h4>The phase III NATALEE trial reported a statistically significant invasive disease-free survival benefit with ribociclib plus nonsteroidal aromatase inhibitor (NSAI) versus an NSAI alone in stage II/III hormone receptor-positive, HER2-negative (HR+/HER2-) early breast cancer. In this study, we report health-related quality of life (HRQOL) data from NATALEE.<h4>Patients and methods</h4>Patients were randomized to receive ribociclib plus NSAI or NSAI alone. Patient-reported outcome scores [European Organisation for Research and Treatment of Cancer core quality of life questionnaire global health status and physical, social, and emotional functioning domains; the supplementary European Organisation for Research and Treatment of Cancer breast cancer-specific QOL questionnaire br"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pagination":["1625-1635"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12010963"],"repository":["biostudies-literature"],"pubmed_title":["Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial."],"pmcid":["PMC12010963"],"pubmed_authors":["Kukielka-Budny B","Rugo HS","Stroyakovskiy D","Chan A","Yardley DA","Nowecki Z","Fasching PA","Fresco R","Chia S","Huang CS","Li Z","Slamon D","Ferrusi I","Hurvitz S","Danyliv A","Untch M","Martin M","Loi S","Hortobagyi G","Afenjar K"],"additional_accession":[]},"is_claimable":false,"name":"Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.","description":"<h4>Purpose</h4>The phase III NATALEE trial reported a statistically significant invasive disease-free survival benefit with ribociclib plus nonsteroidal aromatase inhibitor (NSAI) versus an NSAI alone in stage II/III hormone receptor-positive, HER2-negative (HR+/HER2-) early breast cancer. In this study, we report health-related quality of life (HRQOL) data from NATALEE.<h4>Patients and methods</h4>Patients were randomized to receive ribociclib plus NSAI or NSAI alone. Patient-reported outcome scores [European Organisation for Research and Treatment of Cancer core quality of life questionnaire global health status and physical, social, and emotional functioning domains; the supplementary European Organisation for Research and Treatment of Cancer breast cancer-specific QOL questionnaire br","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-03T04:52:30.012Z","creation":"2025-07-08T03:12:25.078Z"},"accession":"S-EPMC12010963","cross_references":{"pubmed":["40019493"],"doi":["10.1158/1078-0432.CCR-24-1724"]}}